Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

被引：28
作者：
Alperovich, Anna [1 ]
Younes, Anas [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10065 USA
来源：
CANCER JOURNAL | 2016年 / 22卷 / 01期
关键词：
antibody-drug conjugates (ADCs); brentuximab vedotin; CD30; receptors; therapeutic target; OPEN-LABEL; THERAPY;
D O I：
10.1097/PPO.0000000000000168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.
引用
收藏
页码：23 / 26
页数：4
相关论文
共 18 条
  • [1] Abramson JS, 2015, J CLIN ONCOL, P33
  • [2] [Anonymous], BLOOD
  • [3] [Anonymous], BLOOD
  • [4] Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
    Chen, Robert W.
    Palmer, Joycelynne
    Martin, Peter
    Tsai, Nicole
    Kim, Young
    Mott, Michelle
    Sahebi, Firoozeh
    Siddiqi, Tanya
    Popplewell, Leslie L.
    Leonard, John P.
    Shore, Tsiporah B.
    Forman, Stephen J.
    [J]. BLOOD, 2014, 124 (21)
  • [5] Connors JM, 2014, BLOOD, V124, P292
  • [6] FALINI B, 1995, BLOOD, V85, P1
  • [7] Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
    Forero-Torres, Andres
    Holkova, Beata
    Goldschmidt, Jerome
    Chen, Robert
    Olsen, Gregg
    Boccia, Ralph V.
    Bordoni, Rodolfo E.
    Friedberg, Jonathan W.
    Sharman, Jeff P.
    Palanca-Wessels, Maria Corinna
    Wang, Yinghui
    Yasenchak, Christopher A.
    [J]. BLOOD, 2015, 126 (26) : 2798 - 2804
  • [8] Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
    Gopal, Ajay K.
    Ramchandren, Radhakrishnan
    O'Connor, Owen A.
    Berryman, Robert B.
    Advani, Ranjana H.
    Chen, Robert
    Smith, Scott E.
    Cooper, Maureen
    Rothe, Achim
    Matous, Jeffrey V.
    Grove, Laurie E.
    Zain, Jasmine
    [J]. BLOOD, 2012, 120 (03) : 560 - 568
  • [9] How I treat Burkitt lymphoma in adults
    Jacobson, Caron
    LaCasce, Ann
    [J]. BLOOD, 2014, 124 (19) : 2913 - 2920
  • [10] The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies
    Kumar, Ashwini
    Majumder, Muntasir Mamun
    Marti, Jesus Maria Lopez
    Parsons, Alun
    Mattila, Pirkko
    Porkka, Kimmo
    Kallioniemi, Olli
    Heckman, Caroline A.
    [J]. BLOOD, 2014, 124 (21)
12